Ignite Creation Date:
2025-12-25 @ 3:56 AM
Ignite Modification Date:
2026-04-06 @ 9:57 PM
Study NCT ID:
NCT00220402
Status:
COMPLETED
Last Update Posted:
2008-11-24
First Post:
2005-08-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome
Sponsor:
Pfizer
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Overactive Bladder Syndrome | View |
Keywords: